CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Viracta Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Viracta Therapeutics Inc
2533 S COAST HWY 101, SUITE 210
Phone: (858) 400-8470p:858 400-8470 CARDIFF BY THE SEA, CA  92007  United States Ticker: SNSS SNSS
Business Summary
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Roger J.Pomerantz 66 2/24/2021 2/24/2021
President, Chief Executive Officer, Director Mark A.Rothera 60 9/19/2022 9/19/2022
Interim Principal Financial Officer and Interim Principal Accounting Officer MelodyBurcar 41 3/20/2024 3/20/2024
6 additional Officers and Directors records available in full report.

Business Names
Business Name
SNSS
Viracta Royalty Fund, LLC
Viracta Subsidiary, Inc.
VIRX

General Information
Number of Employees: 40 (As of 12/31/2023)
Outstanding Shares: 39,272,434 (As of 3/4/2024)
Shareholders: 52
Stock Exchange: NASD
Federal Tax Id: 943295878
Fax Number: (650) 266-3501


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024